Articles
Targeted therapy with the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence), which is currently approved for the treatment of patients with non-Hodgkin lymphoma, has demonstrated durable remissions in treatment-naïve patients with chronic lymphocytic leukemia (CLL), according to the long-term data from the phase 2 CLL-001 study, which were presented at the ASCO 2020 virtual annual meeting. Read More ›
The combination of carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone (KRd) as induction therapy does not improve outcomes in patients newly diagnosed with multiple myeloma compared with the current standard of care with bortezomib (Velcade), lenalidomide, and dexamethasone (VRd). Read More ›
Cellular therapy is becoming an attractive option for heavily pretreated patients with relapsed or refractory multiple myeloma. According to data presented at the ASCO 2020 virtual annual meeting, 2 chimeric antigen receptor (CAR) T-cell drugs have generated impressive rates of response that are sustainable. Read More ›
During a recent Association for Value-Based Cancer Care (AVBCC) webcast, titled Potential for Cancer Agents in the Treatment of COVID-19, a panel of healthcare experts discussed the latest studies investigating the use of anti-cancer therapies as treatments for COVID-19. Read More ›
New research highlights the importance of germline analysis in the identification of germline alterations for cancer treatment. According to a large analysis presented at the ASCO 2020 virtual annual meeting, nearly 9% of patients with advanced cancer harbor a targetable germline variant. Read More ›
Cemiplimab-rwlc (Libtayo), a new PD-1 inhibitor, has transformed the treatment of advanced cutaneous squamous-cell carcinoma (CSCC), significantly extending survival for patients. Read More ›
By William King
According to results of the phase 3 multinational ADAURA clinical trial, treatment with osimertinib in the adjuvant setting significantly improves disease-free survival in patients with localized non–small-cell lung cancer (NSCLC) with EGFR mutation. Read More ›
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, describe their experiences in the use of niraparib, olaparib and nucaparib as first-line maintenance therapy in Ovarian Cancer. Read More ›
This supplement reviews outcomes from several key trials, examines the use of PARP inhibitors and other emerging treatments, and discusses several changes recently made to treatment recommendations from NCCN and ASCO and how those changes can be incorporated into clinical practice. Read More ›
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, discuss the relative benefits and risks of maintenance therapy in ovarian cancer with bevacizumab versus a PARP inhibitor. Read More ›